|
The Business of Biotech Insights Magazine, Fall 2008 From lab coat to rubber boots: Interview with two emerging companies What does it take to grow an idea into a winning firm? Insights magazine sat down with the CEOs of two emerging Canadian companies, Lignol Energy Corporation and Xenon Pharmaceuticals Inc., to reflect on the early and continuing challenges and successes of these entrepreneurs who have built their companies into the winner of the 2008 Gold Leaf Awards Emerging Company of the Year. Read more OncoGenex shares jump on cancer drug test results - UBC spinoff sees shares jump 76 per cent
By Fiona Anderson December 3, 2008 Shares of OncoGenex Pharmaceuticals Inc. jumped
Wednesday after news that the company's cancer-fighting drug prolonged
the life of those being treated for prostate cancer. The median survival rate for patients who were receiving their first
batch of chemotherapy (called first-line patients) was 16.9 months
while the median for those who also took OncoGenex's OGX-011 was 27.5
months. Read more
A better way to assess drugs, and provide them to those in need December 10, 2008 By Cheryl Koehn and Rennie Hoffman, Special to the Sun Once again the defenders of the Therapeutics Initiative have embarked on a PR campaign to try to save the positions of a small, insulated group of academics receiving millions of dollars from the B.C. government. What we have heard the past week from these TI defenders would not surprise anyone following the Pharmaceutical Task Force ("PTF") process because we have been hearing the same rhetoric from the same ideologically blinkered perspective throughout the past 12 months. Read more Life Sciences in BC Featured on The World at Six December 11, 2008 The recent economic crisis prompted two interview segments with LifeSciences BC President, Karimah Es Sabar and others on CBC Radio. The following links provide download access to audio files of the programs. The World at Six - Interview at minute 15:30 http://www.cbc.ca/w6/index.html The World Report - Interview at minute 10:30 http://www.cbc.ca/worldreport/podcast.html BC Drug Approved by FDA FDA Approves Genzyme’s Mozobil Date: December 15, 2008 Product Provides Enhanced Mobilization of Stem Cells for Autologous Transplantation in Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients Genzyme Corporation (Nasdaq: GENZ) announced today that the U.S. Food and Drug Administration has granted marketing approval for Mozobil™ (plerixafor injection), a drug intended to be used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). The product has also been granted orphan drug designation. Read more Biotech's Change of Heart Business in Vancouver - The WHITE Edition December 2008 iCo Therapeutics Inc. CEO Andrew Rae believes good corporate citizenship is part of the wave of hte future. Expanding their priorities beyond the bottom line, drug-makers are targeting diseases that are endemic in many developing countries, but that have historically been neglected by the biotech industry because of their low-revenue returns... Read more For additional news on the bioproducts and bioenergy sector, please visit our page. |
 Suite 900 - 1188 West Georgia St.
Vancouver, BC V6E 4A2 |